0KF3 주식 개요 팰러틴 테크놀로지스는 미국에서 다양한 질병 치료를 위한 표적 수용체 특이적 치료제를 개발하는 바이오 제약 회사입니다. 자세한 내용
위험 분석 + 2 더 많은 위험
모든 위험 점검 보기 {"enabled":false,"variant":{"name":"disabled","enabled":false},"ready":false,"error":null}
생각, 링크 및 회사 내러티브를 캡처하세요.
Palatin Technologies, Inc. 경쟁사 가격 내역 및 성능
다음에 대한 주가 최고가, 최저가 및 변동 요약 Palatin Technologies 과거 주가 현재 주가 US$0.97 52주 최고치 US$4.16 52주 최저치 US$0.70 베타 0.88 1개월 변경 -13.72% 3개월 변경 사항 -19.12% 1년 변경 사항 -75.41% 3년 변화 -90.65% 5년 변화 n/a IPO 이후 변화 -95.74%
최근 뉴스 및 업데이트
Palatin Technologies, Inc. to Report Q2, 2025 Results on Feb 13, 2025 Feb 11 Palatin Technologies, Inc. has filed a Follow-on Equity Offering in the amount of $4.688 million. Feb 08
Palatin Technologies, Inc. Completes Phase 2 Obesity Study with Mc4r Bremelanotide Plus Glp-1/Gip Tirzepatide Feb 06
New major risk - Shareholder dilution Jan 17
Palatin Technologies, Inc. Announces Positive Phase IIb BREAKOUT Study Results in Patients with Type 2 Diabetic Nephropathy Dec 19
Palatin Technologies, Inc. Announces Completion of Patient Enrollment in Phase 2 Study of Orally Administered Melanocortin Agonist PL8177 in Ulcerative Colitis Nov 26 더 많은 업데이트 보기
Palatin Technologies, Inc. to Report Q2, 2025 Results on Feb 13, 2025 Feb 11 Palatin Technologies, Inc. has filed a Follow-on Equity Offering in the amount of $4.688 million. Feb 08
Palatin Technologies, Inc. Completes Phase 2 Obesity Study with Mc4r Bremelanotide Plus Glp-1/Gip Tirzepatide Feb 06
New major risk - Shareholder dilution Jan 17
Palatin Technologies, Inc. Announces Positive Phase IIb BREAKOUT Study Results in Patients with Type 2 Diabetic Nephropathy Dec 19
Palatin Technologies, Inc. Announces Completion of Patient Enrollment in Phase 2 Study of Orally Administered Melanocortin Agonist PL8177 in Ulcerative Colitis Nov 26
First quarter 2025 earnings released: US$0.39 loss per share (vs US$0.48 loss in 1Q 2024) Nov 17
Palatin Technologies, Inc. to Report Q1, 2025 Results on Nov 14, 2024 Nov 08
Palatin Presents Data on Novel Melanocortin 4 Receptor Selective Oral Small Molecule Pl7737 Obesity Program at Obesityweek 2024 Nov 05
Palatin Technologies, Inc. Completes Enrollment in Phase 2 Clinical Study of Bremelanotide (MC4R Agonist) Co-Administered with Tirzepatide (GLP-1/GIP) for the Treatment of Obesity Nov 01
Palatin Technologies, Inc. Presents Illustrates Data from Clinical and Preclinical Studies for Three Proprietary Melanocortin Agonists Oct 26
Palatin Receives Notice of Non-Compliance from NYSE American Oct 08
New major risk - Revenue and earnings growth Oct 07
Full year 2024 earnings released: US$2.02 loss per share (vs US$2.21 loss in FY 2023) Oct 02
Palatin Technologies, Inc. to Report Q4, 2024 Results on Oct 01, 2024 Sep 27
Palatin Technologies, Inc., Annual General Meeting, Dec 12, 2024 Sep 10
Palatin Technologies, Inc. Announces FDA Confirms Acceptability of Remaining Phase 3 Pivotal Clinical Trials for PL9643 in Dry Eye Disease (DED) Aug 28
Palatin Technologies, Inc. Announces First Patient Dosed in Phase 2 Clinical Study of Bremelanotide Co-Administered with Tirzepatide (GLP-1) for the Treatment of Obesity Aug 22
New major risk - Shareholder dilution Jun 30
Forecast to breakeven in 2027 Jun 30
Palatin Technologies, Inc. Announces Initiation of Phase 2 Clinical Study of Bremelanotide Co-Administered with PDE5i for Treatment of Erectile Dysfunction Jun 20
Palatin Technologies, Inc. Initiates Phase 2 Clinical Study of Bremelanotide for the Treatment of Obesity Jun 15
Palatin Technologies, Inc., Annual General Meeting, Jun 27, 2024 May 31
Third quarter 2024 earnings released: US$0.53 loss per share (vs US$0.63 loss in 3Q 2023) May 17
Palatin Technologies, Inc. to Report Q3, 2024 Results on May 15, 2024 May 11
Palatin Announces Phase 3 Pl9643 Melody-1 Dry Eye Disease (Ded) Clinical Data Results Presented At American Society of Cataract and Refractive Surgery (Ascrs) 2024 Apr 09
No longer forecast to breakeven Feb 17
New minor risk - Profitability Feb 16
Second quarter 2024 earnings released: US$0.56 loss per share (vs US$0.13 loss in 2Q 2023) Feb 15
Palatin Announces Database Lock for PL9643 Melody-1 Pivotal Phase 3 Clinical Trial in Patients with Dry Eye Disease (DED) Feb 05 Palatin Technologies, Inc. has filed a Follow-on Equity Offering in the amount of $10.000006 million. Jan 30
Palatin Technologies, Inc. Provides Corporate Update and Highlights Strategic Priorities for Year 2024 Jan 08
Forecast to breakeven in 2026 Jan 02
Palatin Technologies Receives Notice of Acceptance of the Listing Standards Compliance Plan from NYSE American Dec 19
First quarter 2024 earnings released: US$0.48 loss per share (vs US$0.86 loss in 1Q 2023) Nov 16
New major risk - Negative shareholders equity Nov 16
Palatin Technologies, Inc. to Report Q1, 2024 Results on Nov 14, 2023 Nov 10 Palatin Technologies, Inc. announced that it expects to receive $5.000001 million in funding Oct 24
Palatin Technoloes, Inc. Announces Positive Preclinical Data Showing Synergistic Weight Loss; Initiating Clinical Study of Melanocortin 4 Receptor Agonist + GLP-1 in Obese Patients Oct 19
Palatin Receives Notice of Non-Compliance from NYSE American Oct 15
Palatin Receives Notice of Non-Compliance from NYSE American Oct 14
Full year 2023 earnings released: US$2.53 loss per share (vs US$3.79 loss in FY 2022) Sep 29
Palatin Technologies, Inc. to Report Q4, 2023 Results on Sep 28, 2023 Sep 23
Insufficient new directors Sep 15
Palatin Technologies, Inc. Completes Enrollment in Phase 3 Melody-1 Study of PL9643 for the Treatment of Patients with Dry Eye Disease Sep 09
Palatin Technologies, Inc. Initiates Clinical Program for Bremelanotide Co-Formulated with A Pde5i for the Treatment of Ed in Patients Non-Responsive to Pde5i Treatment Aug 11
Palatin Technologies, Inc.'s Vyleesi Licensee Fosun Pharma Reports First Commercial Sale in China and South Korean Licensee Kwangdong Pharmaceuticals Completes Enrollment in Phase 3 Clinical Study Aug 09
Palatin Technologies, Inc., Annual General Meeting, Jun 20, 2023 May 20
Third quarter 2023 earnings released: US$0.63 loss per share (vs US$0.80 loss in 3Q 2022) May 16
Palatin Technologies, Inc. to Report Q3, 2023 Results on May 16, 2023 May 12
Palatin Technologies, Inc. Presents PL8177 Ulcerative Colitis Data at Digestive Disease Week Annual Conference May 10
Insufficient new directors Apr 18
Second quarter 2023 earnings released: US$0.13 loss per share (vs US$0.91 loss in 2Q 2022) Feb 16
Palatin Technologies, Inc. to Report Q2, 2023 Results on Feb 15, 2023 Feb 11
Insufficient new directors Feb 02
Palatin Technologies Initiates Enrollment in the Phase 2 Bremelanotide BREAKOUT Study in Patients with Diabetic Kidney Disease Jan 20
Frontiers in Immunology Publishes Pre-Clinical Study of Palatin's PL8177 Demonstrating Therapeutic Effects in Inflammatory Conditions Jan 11
Forecast to breakeven in 2025 Dec 07
Insufficient new directors Dec 07
Palatin Technologies, Inc. to Report Q1, 2023 Results on Nov 14, 2022 Nov 10 Palatin Technologies, Inc. has completed a Follow-on Equity Offering in the amount of $9.999921 million. Nov 03
Palatin Technologies, Inc. Announces First Patient Has Been Enrolled in the Pl8177-205 Study with Palatin's Pl8177 Oct 21
Insufficient new directors Oct 13
Full year 2022 earnings released: US$3.79 loss per share (vs US$3.55 loss in FY 2021) Sep 23
Palatin Technologies, Inc. to Report Q4, 2022 Results on Sep 22, 2022 Sep 20
Palatin Announces Initiation of Patient Recruitment for Phase 2 Clinical Study Evaluating Oral PL8177 for Treatment of Ulcerative Colitis Sep 09
Palatin Reports Positive Interim Analysis in Phase 3 Pivotal Study of PL9643 in Patients with Dry Eye Disease Aug 17
Palatin Technologies, Inc. Announces Appointment of Carl Spana as Chief Executive Officer Effective July 1, 2022 Jun 26
Insufficient new directors Jun 06
Palatin Technologies, Inc., Annual General Meeting, Jun 24, 2022 May 25
Third quarter 2022 earnings released: US$0.032 loss per share (vs US$0.024 loss in 3Q 2021) May 18
Palatin Technologies, Inc. to Report Q3, 2022 Results on May 17, 2022 May 12
Insufficient new directors Apr 28
Insufficient new directors Mar 18
Second quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat Feb 15
Palatin Technologies, Inc. to Report Q2, 2022 Results on Feb 15, 2022 Feb 11
Palatin Technologies, Inc. Announces Initiation of Pivotal Phase 3 Pl9643 Melody-1 Clinical Trial in Patients with Dry Eye Disease Dec 29
First quarter 2022 earnings released: US$0.03 loss per share (vs US$0.017 loss in 1Q 2021) Nov 16
Full year 2021 earnings released: US$0.14 loss per share (vs US$0.096 loss in FY 2020) Sep 30
Insufficient new directors Sep 30
Palatin Technologies, Inc. Announces Presentation of Positive Protective Effects of PL8331 and PL9654 on Retinal Inflammation at the 2021 American Society of Retina Specialists (ASRS) Annual Meeting Sep 29
Palatin Technologies, Inc. Announces Positive End-Of-Phase 2 Meeting with FDA on PL9643 for the Treatment of Dry Eye Disease Jun 30
Palatin Technologies, Inc. Announces U.S. Patent Term Extension for Vyleesi May 05
Revenue misses expectations Feb 19
Palatin Technologies, Inc. to Report Q2, 2021 Results on Feb 17, 2021 Feb 13
Palatin Technologies Announces Filing of International Patent Application Claiming PL9643 Feb 11 주주 수익률 0KF3 GB Biotechs GB 마켓 7D 13.3% -2.5% 2.2% 1Y -75.4% -18.4% 13.7%
전체 주주 수익률 보기
수익률 대 산업: 0KF3 지난 1년 동안 -18.4 %를 반환한 UK Biotechs 업계보다 저조한 성과를 냈습니다.
수익률 대 시장: 0KF3 지난 1년 동안 13.7 %를 반환한 UK 시장보다 저조한 성과를 냈습니다.
가격 변동성 Is 0KF3's price volatile compared to industry and market? 0KF3 volatility 0KF3 Average Weekly Movement 20.3% Biotechs Industry Average Movement 7.8% Market Average Movement 4.8% 10% most volatile stocks in GB Market 10.3% 10% least volatile stocks in GB Market 2.6%
안정적인 주가: 0KF3 의 주가는 지난 3개월 동안 UK 시장과 비교해 변동성이 컸습니다.
시간에 따른 변동성: 0KF3 의 주간 변동성 ( 20% )은 지난 1년 동안 안정적이었지만 여전히 UK 의 75%보다 높습니다. 주식.
회사 소개 팰러틴 테크놀로지스는 미국에서 다양한 질병 치료를 위한 표적 수용체 특이적 치료제를 개발하는 바이오 제약 회사입니다. 이 회사의 주요 제품은 폐경 전 여성의 성욕 저하 장애를 치료하는 멜라노코르틴 수용체(MCr) 작용제인 Vyleesi입니다. 또한 염증성 장 질환 치료를 위해 임상 2상 중인 선택적 MC1r 작용제 펩타이드인 경구용 PL8177을 개발 중입니다.
자세히 보기 Palatin Technologies, Inc. 기본 사항 요약 Palatin Technologies 의 수익과 매출은 시가총액과 어떻게 비교하나요? 0KF3 기본 통계 시가총액 US$22.47m 수익(TTM ) -US$32.35m 수익(TTM ) US$2.38m
수익 및 수익 최신 수익 보고서의 주요 수익성 통계(TTM) 0KF3 손익 계산서(TTM ) 수익 US$2.38m 수익 비용 US$23.23m 총 이익 -US$20.84m 기타 비용 US$11.51m 수익 -US$32.35m
주당 순이익(EPS) -1.38 총 마진 -874.25% 순이익 마진 -1,357.06% 부채/자본 비율 0%
0KF3 의 장기적인 성과는 어땠나요?
과거 실적 및 비교 보기
기업 분석 및 재무 데이터 현황 데이터 마지막 업데이트(UTC 시간) 기업 분석 2025/02/11 07:30 장 마감 주가 2025/02/11 00:00 수익 2024/09/30 연간 수익 2024/06/30
데이터 소스 기업 분석에 사용된 데이터는 S&P Global Market Intelligence LLC의 데이터입니다. 이 보고서를 생성하기 위해 분석 모델에 사용된 데이터는 다음과 같습니다. 데이터는 정규화되어 있으므로 소스가 제공되기까지 지연이 발생할 수 있습니다.
패키지 데이터 기간 미국 소스 예시 * 회사 재무 10년 애널리스트 컨센서스 추정치 +3년 시장 가격 30년 소유권 10년 관리 10년 주요 개발 사항 10년
* 미국 증권의 경우, 미국 외 지역의 규제 양식 및 출처는 미국 증권의 예를 사용했습니다.
명시되지 않는 한 모든 재무 데이터는 1년을 기준으로 하지만 분기별로 업데이트됩니다. 이를 후행 12개월(TTM) 또는 최근 12개월(LTM) 데이터라고 합니다. 자세히 알아보기 .
분석 모델 및 눈송이 이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 Github 페이지에서 확인할 수 있으며, 보고서 사용 방법에 대한 가이드와 튜토리얼도 유튜브에서 확인할 수 있습니다.
Simply 월스트리트 분석 모델을 설계하고 구축한 세계적인 수준의 팀에 대해 알아보세요.
산업 및 부문 메트릭 업계 및 섹션 지표는 Simply Wall St에서 6시간마다 계산되며, 자세한 내용은 Github에서 확인할 수 있습니다.
애널리스트 출처 Palatin Technologies, Inc. 5 애널리스트 중 1 애널리스트가 보고서의 입력 자료로 사용된 매출 또는 수익 추정치를 제출했습니다. 애널리스트의 제출 자료는 하루 종일 업데이트됩니다.
분석가 교육기관 John Newman Canaccord Genuity Joseph Pantginis H.C. Wainwright & Co. Kumaraguru Raja NOBLE Capital Markets, Inc.
2 더 많은 분석가 보기 
